Drug
Alxn1830
Alxn1830: highest development phase Phase 2, developed by Alexion. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alexion
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALXN1830 NCT04982289 | Phase 2 | Generalized Myasthenia Gravis |
| ALXN1830 NCT05254613 | Phase 1 | Healthy |
Latest
No recent events.
Follow Alxn1830 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.